Delivery Order HHSN261201200015I-HHSN26100004

This federal contract was awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services (HHS), to the University of Oklahoma (OU) to support the PREVENT Preclinical Drug Development Program. The $884,341.08 firm-fixed-price contract task order is for the development of an EGFR and KRAS vaccine to prevent lung cancer. Key subcontractors include The Methodist Hospital (doing business as Houston Methodist Hospital) and the Medical College of Wisconsin. The...

The National Cancer Institute issued a delivery order to The Institute For Cancer Research on May 3, 2023, under the PREVENT Preclinical Drug Development Program IDC for preclinical efficacy and biomarker studies on sulforaphane for malignant mesothelioma prevention, with a ceiling value of $1,199,274 and an ultimate completion date of May 2, 2027. PREVENT is a National Cancer Institute multiple-award IDC supporting structured preclinical drug and vaccine development across three technical...

The National Cancer Institute (NCI) awarded a $1.1M firm fixed-price delivery order to The University of Texas MD Anderson Cancer Center for the "Targeting STAT3 to Prevent Non-Small Cell Lung Cancer (NSCLC) in Patients with Chronic Obstructive Pulmonary Disease" research project. The award was issued on September 15, 2022, with an ultimate completion date of June 14, 2026, and will be performed in Houston, Texas. This delivery order is issued under the NCI's larger PREVENT Cancer...

This federal contract award, with a ceiling value of $826,870.34, was issued by the National Cancer Institute (NCI) to Northwestern University for a Phase I clinical trial of inhaled iloprost to prevent lung cancer in former smokers. The award is part of the NCI's Cancer Prevention Agent Development Program, which supports early-phase research to evaluate novel cancer prevention agents. Northwestern University, a private research university, is serving as the prime contractor for this work....

The National Cancer Institute issued a delivery order to the University of Oklahoma Health Sciences Center on September 25, 2025, with a ceiling value of $1,234,179, for further development of mitochondria-targeted honokiol for prevention of lung cancer adenocarcinoma and squamous cell carcinoma under the Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ. The parent IDIQ supports preclinical drug development research, including evaluation of efficacy and pharmacodynamic biomarkers...

The Institute For Cancer Research (ICR), a non-profit subsidiary of Temple University, was awarded a $779,932 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program (PREVENT) multiple award master indefinite delivery contract held by the National Cancer Institute. The delivery order, with a completion date of March 2025, will fund continued evaluation of candidate chemopreventive and immunopreventive regimens to support the goals of the PREVENT program in...

This is a firm-fixed price delivery order awarded by the National Cancer Institute, a civilian agency, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The award, valued at $607,113.00, is for a pre-clinical study to investigate the use of aerosolized bexarotene as a chemopreventive agent against the three major subtypes of lung cancer in mouse models. This work is being performed under the Preclinical Agent Development Assays 2012-2016 indefinite delivery...

This is a cost-no-fee delivery order awarded by the National Cancer Institute (NCI) to The Institute for Cancer Research, a non-profit subsidiary of Temple University. The $598,689 contract is for the modulation of cigarette smoke-induced alterations of microRNA expression and lung tumors in mice treated with aspirin and naproxen. This work is being performed under the NCI's Preclinical Efficacy and Intermediate Endpoint Biomarkers multiple-award indefinite delivery contract, which encompasses...

The National Cancer Institute issued a delivery order to The Institute For Cancer Research on May 18, 2022, under the PREVENT Preclinical Drug Development Program (PREVENT), a multiple-award indefinite delivery contract with a $1.24 million ceiling for this order. PREVENT is the National Cancer Institute's structured preclinical drug development vehicle supporting candidate chemopreventive and immunopreventive regimens across three technical pools: Preclinical Efficacy and Biomarkers,...

The University of Oklahoma is the prime contractor on a $911,531 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program IDIQ vehicle held by the National Cancer Institute. The scope of work involves testing the efficacy of combination KRAS or EGFR peptide vaccines and the investigational drug CA-170 to improve immunoprevention against lung tumor progression driven by specific mutations in transgenic animal models. Objectives include determining tolerability...